抗体药物偶联物治疗恶性肿瘤临床应用专家共识(2020版)

抗体药物偶联物(ADC)是一类通过连接头将细胞毒性药物连接到单克隆抗体的靶向生物药剂,以单抗作为载体将小分子细胞毒性药物以靶向方式高效地运输至目标肿瘤细胞中。深入了解ADC药物的分子特征和机制特点,并在ADC药物临床应用过程中根据适应证合理用药,选择合适的剂量和疗程,有效管理不良反应,对临床医师而言十分重要,甚至可能影响患者的生存转归。因此,共识旨在对市面可及的ADC药物进行系统概述,从而为临床医师更好地应用和管理ADC药物提供切实有效的建议和参考。

Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2020 Edition)

Antibody-drug conjugate(ADC)is a type of targeted biological agent which connect cytotoxic drug to monoclonal antibody by a connector head,which enables monoclonal antibody acted as a carrier to efficiently transport small molecular cytotoxic drugs to target tumor cells.It is very important for clinicians to have an in-depth understanding of the molecular characteristics and mechanism of ADC drugs,rationally choose the appropriate dose,course of treatment and manage adverse reactions according to the indications during the clinical application of ADC drugs,which may even affect the survival of patients.Therefore,the consensus aims to conduct a systematic overview of commercially available ADC drugs,provide effective recommendations and references for clinicians to better apply and manage ADC drugs.